Oren Hershkovitz
Chief Executive Officer chez ENLIVEX THERAPEUTICS LTD.
Fortune : 72 605 $ au 31/03/2024
Profil
Oren Hershkovitz is the Chief Executive Officer at Enlivex Therapeutics Ltd.
and also serves as the Director & General Manager at OPKO Biologics Ltd.
He holds a doctorate degree from Ben-Gurion University of the Negev.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 19 157 ( 0,10% ) | 72 605 $ | 31/03/2024 |
Postes actifs de Oren Hershkovitz
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Chief Executive Officer | 16/11/2019 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Director/Board Member | 01/09/2016 |
Formation de Oren Hershkovitz
| Ben-Gurion University of the Negev | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
| Enlivex Therapeutics Ltd. |
